Korean J Dermatol.
2009 Jun;47(6):722-725.
A Case of Psoriasiform Drug Eruption Induced by Imatinib Mesylate (GleevecTM)
- Affiliations
-
- 1 Department of Dermatology, Chonnam National University Medical School, Gwangju, Korea. yhwon@chonnam.ac.kr
Abstract
- Imatinib mesylate (GleevecTM, formerly known as STI571) is an oral drug that selectively inhibits bcr-abl, c-kit and platelet-derived factor receptor (PDGFR) tyrosine kinase. It has been used for treating chronic myelogenous leukemia (CML) and gastrointestinal stromal tumors. Various adverse cutaneous reactions have been reported, yet the development of psoriasis or a psoriasiform drug eruption by the drug has rarely been reported. We herein report on a case of psoriasiform drug eruption that developed after administering imatinib mesylate to treat CML.
Keyword
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- A Case of Lichenoid Drug Eruption Associated with Imatinib Mesylate
- Imatinib-induced Psoriasiform Drug Eruption in a Patient with a Gastrointestinal Stromal Tumor
- Pityriasis rosea-like Drug Eruption Induced by Imatinib Mesylate (Gleevec(TM))
- A Case of Drug Eruption with Localized ExfoliativeDermatitis Induced by Imatinib Mesylate
- Imatinib-induced hepatitis treated by corticosteroids in a patient with metastatic gastrointestinal stromal tumor
